bluebird bio reported a net income of $21.2 million in Q1 2023, a significant turnaround from a net loss of $122.2 million in the same period in 2022, primarily due to a one-time gain from the sale of ...
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today issued a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback